Global companion diagnostics market to reach USD 11.7 billion by 2027

The “Companion diagnostics market: Global industry trends, share, size, growth, opportunity and forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.

The global companion diagnostics market size reached US$ 5.0 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 11.7 Billion by 2027, exhibiting a CAGR of 15.22% during 2021-2027.

Companies mentioned

• Abbott Laboratories
• Agilent Technologies
• BioMerieux
• Danaher Corporation
• Roche Holding AG
• Myriad Genetics Inc.
• Siemens Healthcare
• Thermo Fisher Scientific Inc.

Keeping in mind the uncertainties of Covid-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Companion diagnostics refer to a combination of tests and therapies that provide essential information about corresponding therapeutic products to deliver safe and effective medical care.

These diagnostics also offer an in-depth understanding of disease biology and the mechanism of action (MOA), which help healthcare professionals determine the potential side effects or risks of a therapeutic product on the patient. At present, companion diagnostics are extensively utilized in oncology to deliver targeted therapies and personalized medicines to patients.

The growing prevalence of cancer, in confluence with the escalating demand for in-vitro diagnostics and targeted therapies, represents one of the key factors impelling the global companion diagnostics market growth. Apart from this, personalized healthcare (PHC) and precision medicine are also gaining traction in the treatment of cardiovascular, neurological, infectious and inflammatory diseases, which, in turn, is bolstering the growth of the market.

Furthermore, the escalating demand for next-generation sequencing (NGS), the rising number of clinical trials and the increasing focus on the co-development of drugs and diagnostic technologies are contributing to the market growth.

The introduction of new biomarkers, rising approvals of companion diagnostics and increasing collaboration between companies to develop novel companion diagnostic products are some of the other factors positively influencing the market growth.

Currently, due to the spread of the coronavirus disease (Covid-19), diagnostic service providers are providing test services to healthcare providers. They are also utilizing companion diagnostics to detect the efficacy of Covid-19 drugs among patients undergoing oncology therapies.

Key market segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global companion diagnostics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product & service, technology, indication and end user.

Breakup by product & service:

• Assays, kits and reagents
• Software and services

Breakup by technology:

• Immunohistochemistry (IHC)
• Polymerase Chain Reaction (PCR)
• In-situ Hybridization (ISH)
• Real-time PCR (RT-PCR)
• Gene sequencing
• Others

Breakup by indication:

• Cancer
• Lung cancer
• Breast cancer
• Colorectal cancer
• Gastric cancer
• Melanoma
• Others
• Neurological diseases
• Infectious diseases
• Cardiovascular diseases
• Others

Breakup by end user:

• Pharmaceutical & Bbiopharmaceutical companies
• Reference laboratories
• Contract research Ororganizations
• Others

Research and Markets